What did UBS change in the ABT analyst rating on March 13, 2026?

UBS **maintained a Buy** rating on Abbott Laboratories on March 13, 2026. The firm reiterated confidence in diagnostics and device revenue but did not issue a new price target in that note.

How should investors interpret a maintained Buy for ABT?

A maintained Buy signals steady analyst conviction rather than a new valuation view. It suggests UBS sees ongoing growth drivers but not a fresh catalyst to raise the price target.

Did UBS publish an ABT price target with this rating?

No. UBS did not publish a new ABT price target in the March 13, 2026 note, leaving previous valuations unchanged until further commentary or earnings updates.

How does the Meyka grade reflect this analyst action?

Meyka AI rates ABT with a grade of B+. This grade factors S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. It is informational and not investment advice.

Analyst Ratings

UBS Maintains Buy on Abbott Laboratories (ABT) March 13, 2026

ByHuzaifa Zahoor March 14, 2026March 14, 2026

UBS maintained a Buy rating on Abbott Laboratories (ABT) on March 13, 2026, marking a continued vote of confidence in the company’s medical-device and diagnostics growth. The ABT analyst rating note emphasized durable demand in diagnostic testing and device replacement cycles. UBS did not publish a new price target in the note. Read UBS note on StreetInsider